SCHEMBL7568100

SCHEMBL7568100

Nc1nc2c(ncn2CCC(=O)NCc2ccc3c(c2)OCO3)c(=O)[nH]1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.56
POLB P06746 2/20 0.52
HPGD P15428 1/20 0.52
MAPK1 P28482 2/20 0.48
ALDH1A1 P00352 2/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
TK1 P04183 1/20 0.47
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
LMNA P02545 1/20 0.46
TP53 P04637 1/20 0.46
TSHR P16473 1/20 0.46
KMT2A Q03164 2/20 0.46
CYP1A2 P05177 2/20 0.46
CYP3A4 P08684 2/20 0.46
CYP2D6 P10635 2/20 0.46
CYP2C9 P11712 2/20 0.46
CYP2C19 P33261 2/20 0.46
ADRB2 P07550 1/20 0.46
MEN1 O00255 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7400845 0.86 TDP1 (0.54) TDP1POLBHPGDMAPK1ALDH1A1
SCHEMBL4964128 0.82 PNP (0.63) TK1
SCHEMBL7568086 0.77 POLB (0.52) TDP1POLBHPGDMAPK1ALDH1A1
SCHEMBL7575997 0.77 TK1 (0.51) POLBALDH1A1TK1TSHRKMT2A
SCHEMBL7567095 0.77 TK1 (0.60) TK1TSHRUSP2
SCHEMBL7574667 0.76 PNP (0.52) POLBTK1TSHRCYP1A2CYP3A4
SCHEMBL7570078 0.76 TK1 (0.65) ALDH1A1TK1LMNATSHRKMT2A
SCHEMBL7575116 0.76 TK1 (0.59) TK1TSHRUSP2
SCHEMBL7576803 0.74 TK1 (0.60) TK1
SCHEMBL7982329 0.74 TK1 (0.57) TK1TSHRUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6297226-B1 TREATING A DISEASE OR A CONDITION IN A MAMMAL TREATABLE BY INHIBITING THE ACTIVITY OF A MONOAMINE OXIDASE NEOTHERAPEUTICS, INC. 2001-10-02 US claimed
EP-1237890-A1 SYNTHESIS AND METHODS OF USE OF 9-SUBSTITUTED GUANINE DERIVATIVES Neotherapeutics, Inc. (US) 2002-09-11 EP disclosed
US-6297226-B1 TREATING A DISEASE OR A CONDITION IN A MAMMAL TREATABLE BY INHIBITING THE ACTIVITY OF A MONOAMINE OXIDASE NEOTHERAPEUTICS, INC. 2001-10-02 US disclosed
WO-2001029039-A1 SYNTHESIS AND METHODS OF USE OF 9-SUBSTITUTED GUANINE DERIVATIVES NEOTHERAPEUTICS, INC. (US) 2001-04-26 WO disclosed